Statement On Safe Use of Propofol
Statement On Safe Use of Propofol
Statement On Safe Use of Propofol
(Approved by the ASA House of Delegates on October 27, 2004, and amended on
October 15, 2014)
Because sedation is a continuum, it is not always possible to predict how an individual patient
will respond. Due to the potential for rapid, profound changes in sedative/anesthetic depth and
the lack of antagonist medications, agents such as propofol require special attention. Even if
moderate sedation is intended, patients receiving propofol should receive care consistent with that
required for deep sedation.
The Society believes that the involvement of an anesthesiologist in the care of every patient
undergoing anesthesia is optimal. However, when this is not possible, non-anesthesia personnel
who administer propofol should be qualified to rescue* patients whose level of sedation becomes
deeper than initially intended and who enter, if briefly, a state of general anesthesia.**
The physician responsible for the use of sedation/anesthesia should have the education and
training to manage the potential medical complications of sedation/anesthesia. The physician
should be proficient in airway management, have advanced life support skills appropriate for
the patient population, and understand the pharmacology of the drugs used.
The physician should be physically present throughout the sedation and remain immediately
available until the patient is medically discharged from the post procedure recovery area.
The practitioner administering propofol for sedation/anesthesia should, at a minimum, have
the education and training to identify and manage the airway and cardiovascular changes
which occur in a patient who enters a state of general anesthesia, as well as the ability to
assist in the management of complications.
The practitioner monitoring the patient should be present throughout the procedure and be
completely dedicated to that task.
During the administration of propofol, patients should be monitored without interruption to
assess level of consciousness, and to identify early signs of hypotension, bradycardia, apnea,
airway obstruction and/or oxygen desaturation. Ventilation, oxygen saturation, heart rate and
blood pressure should be monitored at regular and frequent intervals. Monitoring for the
presence of exhaled carbon dioxide should be utilized unless invalidated by the nature of the
patient, procedure or equipment because movement of the chest will not dependably identify
airway obstruction or apnea.
Age-appropriate equipment must be immediately available for the maintenance of a patent
airway, oxygen enrichment and artificial ventilation in addition to circulatory resuscitation.
is consistent with the principles set forth in this statement.
The Warnings section of the drugs package insert (Diprivan, AstraZeneca 08/05, accessed
1-09) states that propofol used for sedation or anesthesia should be administered only by persons
trained in the administration of general anesthesia and not involved in the conduct of the
surgical/diagnostic procedure. Patients should be continuously monitored, and facilities for
1
maintenance of a patent airway, artificial ventilation, and oxygen enrichment and circulatory
resuscitation must be immediately available.
In addition, some states have prescriptive regulations concerning the administration of propofol.
There are different considerations when propofol is used for sedation of intubated, ventilated
patients in a critical care setting.
Similar concerns apply when other intravenous induction agents such as methohexital or
etomidate are used for sedation. Administering combinations of drugs including sedatives and
analgesics may increase the likelihood of adverse outcomes.